… (AONs) have been used as therapeutics for the last few decades. ProQR has built an extensive pipeline of investigational RNA therapies based on the technologies already available. We have gone beyond that and are …
… specific RNA for A-to-I editing by recruiting endogenous Adenosine Deaminase Acting on RNA (ADAR). This presentation will highlight the therapeutic …
… specific RNA for A-to-I editing by recruiting endogenous Adenosine Deaminase Acting on RNA (ADAR). Through now further developed design principles there …
… against opposition filed against a key patent for its ADAR-mediated RNA editing platform Axiomer™. The opposition … stability and recruit endogenous ADAR to edit the target adenosine. This patent is part of ProQR’s intellectual …
This is Gerard Platenburg's presentation at the 5th International Conference on Base Editing, Prime Editing & Related Enzymes (Deaminet 2024) in San Diego, California.
… A. de Boer, Founder and CEO, will participate in the ADAR Editing Panel at the Chardan 7 th Annual Genetic … am – 10:15 am EDT, and a recording of the session will be made available on the Company’s website after the conference. … molecular machinery that is present in human cells called ADAR (Adenosine Deaminase Acting on RNA). Axiomer ® EONs are …
… Year End 2024 Operating and Financial Results Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on …
… title: Harnessing chemical modifications to improve ADAR potency and unlock Axiomer broad applicability Presenter: Lenka van Sint Fiet, PhD, … effective strategies to increase RNA editing yields of ADARs using chemical modifications and oligonucleotide design …
… Diseases ProQR scientists report for the first time in the ADAR RNA editing field in vivo proof of target engagement (RNA editing) leading to meaningful changes in biomarkers in NHPs using … molecular machinery that is present in human cells called ADAR (Adenosine Deaminase Acting on RNA). Axiomer EONs are …
